Skip to main content

trtusa.info

Educational information only — not medical advice. TRT requires a licensed prescriber and lab testing. How to start safely

Treatment options: injections, gels, pellets, patches — TRT USA

Overview · 4-minute read

Injections, gels, pellets, patches: the trade-offs in one page.

Medically reviewed by [Reviewer Name], MD Reviewed Aug 4, 2026

All four delivery methods work — they differ in cost, dose stability, and daily hassle more than in effectiveness. Here is the honest one-paragraph version of each.

Injections

The least expensive and most adjustable option, usually weekly or twice-weekly at home. Downsides: needles, and levels that peak and dip between doses unless the schedule is tuned. This is where most careful prescribers start.

Daily gels

Steadier day-to-day levels and no needles, but they cost more, absorb inconsistently in some men, and carry a real transfer risk — skin contact can pass testosterone to partners and children before it dries.

Pellets

Implanted under the skin every 3–6 months in a minor office procedure. Convenient — but the dose cannot be adjusted once implanted, and if side effects appear, you wait them out or have the pellets removed.

Patches

Daily, steady, needle-free. The trade-off is frequent skin irritation, which is why patches are the least commonly chosen of the four.

The pattern: injections trade convenience for control and cost; gels and patches trade cost for steadiness; pellets trade adjustability for convenience. There is no universally best method — only a best fit for your routine, budget, and follow-up plan.

Deciding between methods? USTRT's full comparison covers dosing schedules, monthly costs, switching between methods, and questions to ask about each.

See the full comparison on USTRT →

Sources

  1. American Urological Association — "Evaluation and Management of Testosterone Deficiency: AUA Guideline." 2018.
  2. Journal of Clinical Endocrinology & Metabolism — Bhasin S, et al. Endocrine Society Clinical Practice Guideline. 2018.